The FDA authorized afatinib for treating patients with metastatic NSCLC who had an EGFR mutation (EGFR exon 19 deletions or exon 21 (L858R) replacement mutations) [24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.